Financials

News Ideas Discussions Technicals Seasonals

ENTO fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its pipeline includes Latiglutenase, Capeserod, Adrulipase, and Niclosamide. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

ENTO has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company